Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Fletcher

Showing results (111-120 of 114) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 114 results.
Nature Communications|November 26, 2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trialI'ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, et al.
The Lancet. Infectious Diseases|October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trialSaye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.
The Journal of Antimicrobial Chemotherapy|August 27, 2021
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled studySaye H Khoo, Richard Fitzgerald, Thomas Fletcher, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 27, 2019
Image-based analysis and long-term clinical outcomes of deep brain stimulation for Tourette syndrome: a multisite studyKara A Johnson, P Thomas Fletcher, Domenico Servello, et al.
Pageof 12

Showing results (111-120 of 114) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 114 results.
Nature Communications|November 26, 2022
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trialI'ah Donovan-Banfield, Rebekah Penrice-Randal, Hannah Goldswain, et al.
The Lancet. Infectious Diseases|October 22, 2022
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trialSaye H Khoo, Richard FitzGerald, Geoffrey Saunders, et al.
The Journal of Antimicrobial Chemotherapy|August 27, 2021
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled studySaye H Khoo, Richard Fitzgerald, Thomas Fletcher, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 27, 2019
Image-based analysis and long-term clinical outcomes of deep brain stimulation for Tourette syndrome: a multisite studyKara A Johnson, P Thomas Fletcher, Domenico Servello, et al.
Pageof 12